Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.

A new enantiomeric synthesis utilizing classical resolution provided two novel series of optically active inhibitors of cholinesterase: (-)- and (+)-O-carbamoyl phenols of tetrahydrofurobenzofuran and methanobenzodioxepine. An additional two series of (-)- and (+)-O-carbamoyl phenols of pyrroloindole and furoindole were obtained by known procedures, and their anticholinesterase actions were similarly quantified against freshly prepared human acetyl- (AChE) and butyrylcholinesterase (BChE). Both enantiomeric forms of each series demonstrated potent cholinesterase inhibitory activity (with IC(50) values as low as 10 nM for AChE and 3 nM for BChE), with the exception of the (+)-O-carbamoyl phenols of pyrroloindole, which lacked activity (IC(50) values >1 microM). Based on the biological data of these four series, a structure-activity relationship (SAR) analysis was provided by molecular volume calculations. In addition, a probable transition-state model was established according to the known X-ray structure of a transition-state complex of Torpedo californica AChE-m-(N,N,N-trimethylammonio)-2,2,2-trifluoroacetophenone (TcAChE-TMTFA). This model proved valuable in explaining the enantioselectivity and enzyme subtype selectivity of each series. These carbamates are more potent than, or similarly potent to, anticholinesterases in current clinical use, providing not only inhibitors of potential clinical relevance but also pharmacological tools to define drug-enzyme binding interactions within an enzyme crucial in the maintenance of cognition and numerous systemic physiological functions in health, aging, and disease.

[1]  F. J. Luque,et al.  Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. , 2005, Journal of medicinal chemistry.

[2]  N. Greig,et al.  Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides. , 2005, The Journal of organic chemistry.

[3]  N. Greig,et al.  An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 2005, Current Alzheimer research.

[4]  Zoran Radić,et al.  In situ selection of lead compounds by click chemistry: target-guided optimization of acetylcholinesterase inhibitors. , 2005, Journal of the American Chemical Society.

[5]  Hiroaki Kazui,et al.  Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? , 2005, The American journal of psychiatry.

[6]  S. Arnold,et al.  A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? , 2005, Trends in pharmacological sciences.

[7]  Patrick Masson,et al.  Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. , 2005, Biochemistry.

[8]  J. Becker,et al.  Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition , 2005, Journal of the American Geriatrics Society.

[9]  N. Greig,et al.  Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. , 2004, Current pharmaceutical design.

[10]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[11]  D. Small Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? , 2004, Trends in Neurosciences.

[12]  N. Greig,et al.  Racemic N1-norphenserine and its enantiomers: Unpredicted inhibition of human acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro , 2003 .

[13]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[14]  J. Sussman,et al.  A neutral molecule in a cation-binding site: specific binding of a PEG-SH to acetylcholinesterase from Torpedo californica. , 2002, Journal of molecular biology.

[15]  N. Greig,et al.  Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. , 2002, Journal of medicinal chemistry.

[16]  F. J. Luque,et al.  3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. , 2002, Biochemistry.

[17]  N. Greig,et al.  Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. , 2001, Journal of medicinal chemistry.

[18]  H. Soreq,et al.  Acetylcholinesterase — new roles for an old actor , 2001, Nature Reviews Neuroscience.

[19]  N. Greig,et al.  4′-Hydroxyphenylcarbamates of (3aS)-Eseroline and (3aS)-N(1)-Noreseroline: Potential Metabolites of the Alzheimer′s Anticholinesterase Drug Phenserine. , 1999 .

[20]  N. Greig,et al.  Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. , 1999, Journal of medicinal chemistry.

[21]  J L Sussman,et al.  A preliminary comparison of structural models for catalytic intermediates of acetylcholinesterase. , 1999, Chemico-biological interactions.

[22]  C. Bartolucci,et al.  "Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. , 1999, Biochemistry.

[23]  E. Perola,et al.  Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. , 1997, Biochimica et biophysica acta.

[24]  S. Ōmura,et al.  Arisugacins, selective acetylcholinesterase inhibitors of microbial origin. , 1997, Pharmacology & therapeutics.

[25]  S. Lifson,et al.  External and internal electrostatic potentials of cholinesterase models. , 1997, Journal of molecular graphics & modelling.

[26]  J. Sussman,et al.  Electrooptical measurements demonstrate a large permanent dipole moment associated with acetylcholinesterase. , 1996, Biophysical journal.

[27]  J. Sussman,et al.  The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. , 1996 .

[28]  N. Greig,et al.  Phenserine and ring C hetero‐analogues: Drug candidates for the treatment of Alzheimer's disease , 1995, Medicinal research reviews.

[29]  J. Sussman,et al.  Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents. , 1994, Biochemical Society transactions.

[30]  A. Gnatt,et al.  Excavations into the active-site gorge of cholinesterases. , 1992, Trends in biochemical sciences.

[31]  N. Greig,et al.  Physovenines: Efficient Synthesis of (‐)‐ and (+)‐Physovenine and Synthesis of Carbamate Analogues of (‐)‐Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. , 1991 .

[32]  N. Greig,et al.  Physovenines: Efficient Synthesis of (−)- and (+)-Physovenine and Synthesis of Carbarnate Analogues of (−)-Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines† , 1991 .

[33]  A. Brossi,et al.  Alfred Burger award address. Bioactive alkaloids. 4. Results of recent investigations with colchicine and physostigmine. , 1990, Journal of medicinal chemistry.

[34]  J. Sufrin,et al.  Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. , 1981, Molecular pharmacology.

[35]  D. Drachman,et al.  Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.

[36]  J. Sussman,et al.  Acetylcholinesterase , 2007, Journal of Molecular Neuroscience.

[37]  N. Inestrosa,et al.  Acetylcholinesterase Interaction with Alzheimer Amyloid β , 2005 .

[38]  N. Inestrosa,et al.  Acetylcholinesterase interaction with Alzheimer amyloid beta. , 2005, Sub-cellular biochemistry.

[39]  N. Greig,et al.  Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. , 2005, Journal of medicinal chemistry.

[40]  N. Viguié,et al.  Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization. , 2002, European journal of biochemistry.

[41]  J. Cummings,et al.  Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.

[42]  Z. Radić,et al.  Mechanism of action of cholinesterase inhibitors , 2000 .

[43]  R. Schowen,et al.  Transition States of Biochemical Processes , 1978, Springer US.

[44]  R. Dawson The alkaloids. , 1948, Annual review of biochemistry.